Document:

<PAGE>   1

                                                                     EXHIBIT 4.3

NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")
OR ANY OTHER APPLICABLE SECURITIES LAWS IN RELIANCE UPON AN EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS.
NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE HEREOF MAY BE SOLD,
PLEDGED, TRANSFERRED, ENCUMBERED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR IN A TRANSACTION
WHICH IS EXEMPT FROM REGISTRATION UNDER THE PROVISIONS OF THE SECURITIES ACT.

                             AVANIR PHARMACEUTICALS

                          COMMON STOCK PURCHASE WARRANT

        1. Issuance. In consideration of good and valuable consideration, the
receipt of which is hereby acknowledged by AVANIR PHARMACEUTICALS, a California
corporation (the "Company"), [Holder], (the "Holder") is hereby granted the
right to purchase at any time commencing January 31, 2000 until 5:00 P.M., New
York City time, on January 31, 2004 (the "Expiration Date"),
[______________________________ (___________)] fully paid and nonassessable
shares (the "Warrant Shares") of the Company's Class A Common Stock, no par
value ("Common Stock") at an initial exercise price of $_________ per share (the
"Exercise Price"), subject to further adjustment as set forth in Section 6
hereof. In the event of any conflict between the terms of this Warrant and the
Common Stock Purchase Agreement between the Company and the Holder, dated as of
January 25, 2000 (the "Purchase Agreement"), pursuant to which this Warrant has
been issued, the Purchase Agreement shall control. Capitalized terms used and
not otherwise defined herein shall have the meanings set forth for such terms in
the Purchase Agreement.

        2. Exercise of Warrants.

               (a) This warrant (this "Warrant") is exercisable in whole or in
part at the Exercise Price per share of Common Stock payable hereunder, payable
in cash or by certified or official bank check, or by "cashless exercise," by
means of tendering this Warrant to the Company to receive a number of shares of
Common Stock equal to: (i) the Market Value of the Warrant Shares issuable upon
exercise of this Warrant, less; (ii) the aggregate cash amount of the Exercise
Price of such Warrant Shares, divided by the Market Value per Share. Upon
surrender of this Warrant with the annexed Notice of Exercise of Warrant duly
executed, together with payment of the Exercise Price for the applicable Warrant
Shares exercised, the Holder shall be entitled to receive a certificate or
certificates for the Warrant Shares so exercised. For the purposes of this
Section 2, "Market Value" shall be the amount equal to the average closing bid
price of a share of Common Stock for the ten (10) days preceding the Company's
receipt of the Notice of Exercise of Warrant duly

<PAGE>   2

executed by the Holder multiplied by the number of Warrant Shares to be issued
upon surrender of this Warrant.

               (b) For purposes of Rule 144 promulgated under the Securities
Act, it is intended, understood and acknowledged that the Warrant Shares issued
in a cashless exercise transaction shall be deemed to have been acquired by the
Holder and the holding period for the Warrant Shares shall be deemed to have
been commenced, on the issue date of this Warrant.

        3. Reservation of Shares. The Company hereby agrees that, at all times
during the term of this Warrant, there shall be reserved for issuance upon
exercise of this Warrant such number of shares of Common Stock as shall be
required for issuance upon exercise of this Warrant of the remaining Warrant
Shares.

        4. Mutilation or Loss of Warrant. Upon receipt by the Company of
evidence satisfactory to it of the loss, theft, destruction or mutilation of
this Warrant, and (in the case of loss, theft or destruction) receipt of
reasonably satisfactory indemnification, and (in the case of mutilation) upon
surrender and cancellation of this Warrant, the Company will execute and deliver
a new warrant of like tenor and date and any such lost, stolen, destroyed or
mutilated warrant shall thereupon become void.

        5. Rights of the Holder. The Holder shall not, by virtue hereof, be
entitled to any rights of a shareholder in the Company, either at law or equity,
and the rights of the Holder are limited to those expressed in this Warrant and
are not enforceable against the Company except to the extent set forth herein.

        6. Protection Against Dilution.

               6.1 Adjustment Mechanism. If an adjustment of the Exercise Price
is required pursuant to this Section 6, the Holder shall be entitled to purchase
such number of additional shares of Common Stock as will cause (i) the total
number of shares of Common Stock that the Holder is entitled to purchase
pursuant to this Warrant, multiplied by (ii) the adjusted Exercise Price per
share, to equal the dollar amount of the total number of shares of Common Stock
that the Holder is entitled to purchase before adjustment multiplied by the
Exercise Price before adjustment.

               6.2 Capital Adjustments. In case of any stock split or reverse
stock split, stock dividend, reclassification of the Common Stock,
recapitalization, merger or consolidation, or like capital adjustment affecting
the Common Stock of the Company, the provisions of this Section 6 shall be
applied as if such capital adjustment event had occurred immediately prior to
the date of this Warrant and the original purchase price had been fairly
allocated to the stock resulting from such capital adjustment; and in other
respects the provisions of this section shall be applied in a fair, equitable
and reasonable manner so as to give effect, as nearly as may be, to the purposes
hereof.

                                       2
<PAGE>   3
A rights offering to shareholders shall be deemed a stock dividend to the extent
of the bargain purchase element of the rights.

        7. Transfer to Comply with the Securities Act; Registration Rights.

               (a) This Warrant has not been registered under the Securities Act
and has been issued to the Holder for investment and not with a view to the
distribution of either this Warrant or the Warrant Shares. Neither this Warrant
nor any of the Warrant Shares or any other security issued or issuable upon
exercise of this Warrant may be sold, transferred, pledged or hypothecated in
the absence of an effective registration statement under the Securities Act
relating to such security or an opinion of counsel satisfactory to the Company
that registration is not required under the Securities Act. Each certificate for
this Warrant, the Warrant Shares and any other security issued or issuable upon
exercise of this Warrant shall contain a legend on the face thereof, in form and
substance satisfactory to counsel for the Company, setting forth the
restrictions on transfer contained in this section.

               (b) The Company agrees to file a registration statement, which
shall include the Warrant Shares, on Form S-1 or other available form (the
"Registration Statement"), pursuant to the Registration Rights Agreement, dated
as of January 25, 2000, between the Company and the Holder.

        8. Notices. Any notice or other communication required or permitted
hereunder shall be in writing and shall be delivered personally, telegraphed,
telexed, sent by facsimile transmission or sent by certified, registered or
express mail, postage pre-paid. Any such notice shall be deemed given when so
delivered personally, telegraphed, telexed or sent by facsimile transmission,
or, if mailed, two days after the date of deposit in the United States mails, as
follows:

               (a) If to the Company:

                   Avanir Pharmaceuticals
                   9393 Towne Centre Drive, Suite 200
                   San Diego, California 92121-3016
                   Attention: Gregory P. Hanson, Chief Financial Officer
                   Tel No.: (858) 410-2670
                   Fax No.: (858) 455-8059

                                       3
<PAGE>   4

                   with a copy to:

                   Baker & McKenzie
                   101 West Broadway, Twelfth Floor
                   San Diego, California 92101-3890
                   Attention: Carlos D. Heredia, Esq.
                   Tel No.: (619) 235-7774
                   Fax No.: (619) 236-0429

              (ii) If to the Holder:

                   [________________]
                   [________________]
                   [________________]
                   Attention: [________________]
                   Tel No.:   [________________]
                   Fax No.:   [________________]

                   with a copy to:

                   [________________]
                   [________________]
                   [________________]
                   Attention: [________________]
                   Tel No.:   [________________]
                   Fax No.:   [________________]

Any party may designate another address or person for receipt of notices
hereunder by notice given to the other parties in accordance with this section.

        9. Delivery of Certificates. If the Company fails to deliver to the
Holder certificate or certificates representing the Warrant Shares pursuant to
Section 3(f) by the fifth (5th) Business Day after the Date of Exercise, the
Company shall pay to the Holder, in cash, as liquidated damages and not as a
penalty, $1,000 for each day after such fifth (5th) Business Day until such
certificates are delivered. Nothing herein shall limit the Holder's right to
pursue actual damages for the Company's failure to deliver certificates
representing the Warrant Shares of Common Stock upon exercise within the period
specified herein, except that such liquidated damages paid by the Company to the
Holder shall constitute payment for and offset any such actual damages. The
Holder shall have the right to pursue all remedies available to it at law or in
equity including, without limitation, a decree of specific performance and/or
injunctive relief. The exercise of any such rights

                                       4

<PAGE>   5

shall not prohibit the Holder from seeking to enforce damages pursuant to any
other section hereof or under applicable law.

        10. Supplements and Amendments; Whole Agreement. This Warrant may be
amended or supplemented only by an instrument in writing signed by the parties
hereto. This Warrant contains the full understanding of the parties hereto with
respect to the subject matter hereof and there are no representations,
warranties, agreements or understandings other than expressly contained herein.

        11. Governing Law. This Warrant shall be deemed to be a contract made
under the laws of the State of California and for all purposes shall be governed
by and construed in accordance with the laws of such state applicable to
contracts to be made and performed entirely within such state.

        12. Descriptive Headings. Descriptive headings of the several sections
of this Warrant are inserted for convenience only and shall not control or
affect the meaning or construction of any of the provisions hereof.

        IN WITNESS WHEREOF, the Company has executed this Warrant as of the ____
day of January, 2000.

                                            AVANIR PHARMACEUTICALS

                                            By:
                                               ---------------------------------
                                               Gregory P. Hanson, Chief
                                               Financial Officer

                                       5
<PAGE>   6

                          NOTICE OF EXERCISE OF WARRANT

        The undersigned hereby irrevocably elects to exercise the right,
represented by the AVANIR Pharmaceuticals Common Stock Purchase Warrant dated as
of January 25, 2000, to purchase [__________] shares of the Common Stock, no par
value, of AVANIR Pharmaceuticals and tenders herewith payment in accordance with
said Common Stock Purchase Warrant.

        Please deliver the stock certificate to:

        [______________]
        [______________]
        [______________]
        [______________]
        [______________]

Dated: ______________________

By: __________________________________
Its: _________________________________

(TM)   CASH: $ _______________________

                                       6Exhibit - 10 i

                         INVESTMENT ADVISORY CONTRACT

AGREEMENT, made by and between  The Scott James Fund, Inc.,  a Virginia
Corporation, (hereinafter called "Fund") and  The Scott S. James Company, a
Virginia Corporation (hereinafter called "Investment Adviser")

WITNESSETH: WHEREAS, Fund engages in the business  of investing and  reinvesting
its assets and property in various stocks and securities  and Investment Adviser
engages in the business of providing investment advisory services.

1.  The Fund  hereby employs the  Investment Adviser, for the  period set  forth
    in Paragraph  6 hereof, and on the terms set forth herein, to render invest-
    ment advisory  services  to the Fund.  The  Investment Adviser hereby ac-
    cepts such employment and agrees, during such period, to render the services
    and  assume the obligations herein set forth, for the compensation provided.
    The Investment Adviser shall, for all purposes  herein,  be  deemed to be an
    independent contractor, and shall,  unless otherwise expressly provided  and
    authorized,  have no authority to act  for or represent the Fund in any way,
    or in any way be deemed an agent of the Fund.

2.  As a compensation for the services to be rendered to the Fund by the Invest-
    ment Adviser under the provisions of this  Agreement,  the Fund shall pay to
    the Investment Adviser monthly a fee equal to one-twelfth of one percent per
    month,  (the  equivalent of 1% per annum) of the daily average net assets of
    the Fund  during the month.  The first  payment  of fee  hereunder  shall be
    prorated on a daily basis from the date this Agreement takes  effect but may
    be waived by the Investment Adviser under especial circumstances.

3.  It is expressly understood and  agreed that the  services to be  rendered by
    the Investment Adviser to the Fund  under the  provisions of this  Agreement
    are not to be deemed to be exclusive,  and the  Investment  Adviser shall be
    free to render different services to others so long as its ability to render
    the services provided for in this Agreement shall not be impaired thereby.

4.  It is understood and agreed that directors, officers, employees, agents  and
    shareholders of the Fund may be interested in the Investment Adviser as dir-
    ectors, officers, employees, agents and  shareholders,  and that  directors,
    officers, employees,  agents and shareholders of the  Investment Adviser may
    be interested in the Fund,  as directors,  officers,  employees,  agents and
    shareholders or otherwise,  and that the Investment Adviser,  itself, may be
    interested in the  Fund as a  shareholder or otherwise, specifically,  it is
    understood and agreed that directors, officers, employees, agents and share-
    holders of the  Investment Adviser may continue as directors, officers, emp-
    loyees,  agents and shareholders of the Fund;  that the Investment  Adviser,
    its directors, officers, employees,  agents and  shareholders may  engage in
    other business, may render investment advisory services to other  investment
    companies, or to any other corporation, association, firm or individual, may
    render underwriting services to the Fund, or to any other  investment compa-
    ny, corporation, association,  form or individual.   The Fund shall bear ex-
    penses and salaries necessary and incidental to the conduct of its business,
    including but not in limitation  of the foregoing, the costs incurred in the
    maintenance of its own books, records, and procedures; dealing  with its own
    shareholders; the payment of dividends; transfers of stock  (including issu-
    ance & redemption of shares); reports and  notices to shareholders; expenses
- 1 -
    of annual stockholders; meetings;  miscellaneous office expenses;  brokerage
    commissions; taxes; and custodian, legal, accounting and registration  fees.
    Employees, officers  and agents of the Investment Adviser who are, or may in
    the future be, directors and/or senior officers of the Fund shall receive no
    remuneration  from the Fund  or acting in such capacities  for the Fund.  In
    the conduct  of the respective businesses of  the parties hereto and  in the
    performance of this agreement, the Fund & Investment Adviser  may share com-
    mon facilities and  personnel common to each,  with appropriate proration of
    expenses.

5.  Investment Adviser shall give the Fund the benefit of its best judgment  and
    efforts in rendering these services, and Fund agrees as an inducement to the
    undertaking of these services that Investment Adviser  shall not  be  liable
    hereunder for any mistake of judgment or any event whatsoever, provided that
    nothing herein shall be deemed to protect, or purport to protect, Investment
    Adviser against any liability  to  Fund or to its security holders  to which
    Investment Adviser would otherwise  be subject by reason of willful misfeas-
    ance, bad faith or gross negligence  in the performance of duties hereunder,
    or by reason of reckless disregard of obligations and duties hereunder.

6.  This agreement shall become effective XXXXXX XX, XXXX and continue in effect
    until YYYYYYY YY, YYYY and, thereafter, only so long as  such continuance is
    approved  at least annually  by votes of the Fund's Board of Directors, cast
    in person  at a meeting  called for the purpose  of voting on such approval,
    including votes  of a majority of the  Directors who are not parties to such
    agreement  or interested persons  of any such  party.  This agreement may be
    terminated at any time  upon 60 days prior  written notice, without  payment
    of any penalty, by the Fund's Board of Directors or by vote of a majority of
    the outstanding voting securities of the Fund.  The contract  will automati-
    cally terminate  in the event of  its assignment  by the  Investment Adviser
    (within the  meaning of the  Investment Company Act of 1940), which shall be
    deemed to include transfer of control  of the Investment Adviser.  Upon ter-
    mination of  this agreement, the  obligations of all parties hereunder shall
    cease and terminate as of the date of such termination, except for any obli-
    gation  to respond for  a breach of  this Agreement committed prior to  such
    termination  and except for the obligation of the Fund to pay to the Invest-
    ment Adviser the fee provided in Paragraph 2 hereof, prorated to the date of
    termination.

7.  This Agreement shall not be assigned by the Fund without  prior written con-
    sent thereto of the Investment  Adviser.  This Agreement shall terminate au-
    tomatically in the event of its assignment  by the Investment Adviser unless
    an exemption from such automatic termination is  granted by order or rule of
    the Securities and Exchange Commission.

    IN WITNESS WHEREOF, the parties hereto have caused their corporate  seals to
    be affixed and duly attested and their presence  to be signed  by their duly
    authorized officers this XXth day of XXXXXXX, XXXX.

       The Scott James Fund, Inc.              By _____________________________
                                                   Scott S. James, President
       Attest: ___________________________
               Zhifeng Sun, Director

       The Scott S. James Company               By _____________________________
                                                   Scott S. James, President
       Attest: Zhifeng Sun, Director        - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]